G2B Pharma Inc

G2B Pharma’s research is focused on the development of a needle-free alternative for epinephrine using the nasal delivery route. G2B is partnering in this effort with Shin Nippon Biological Laboratories of Japan, a leading developer of nasal spray devices and delivery systems. Our primary product candidate, G2B011, is a nasal spray formulation of epinephrine for the treatment of anaphylaxis. Anaphylaxis is a severe and life-threatening allergic reaction that affects tens of millions of people worldwide. Common causes of anaphylactic reactions include food allergies and bee stings. Epinephrine is the gold standard for treatment of anaphylaxis and is currently provided for self-administration by injection. The company believes that nasal administration offers an effective and more patient-friendly delivery route for this life-saving medication.